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Purpose: To evaluate results, prognostic
tactors and patterns ot tailure ot the
postoperative radiotherapy (PRT) tor Low-Grade
Gliomas (LGG).
Methods:· Setween 1985 and 1995, 158
patients with LGG (WHO II) received PRT.
There .were 116 astrocytomas, 17 mixed
oligoastrocytomas, 25 oligodendrogliomas.
Median age was 39 years (range: 17-74).
Conventional treatment techniques and doses
were employed (median total dose- 58 Gy,
median dose per traction - 2 Gy). Ali known
parameters with possible intluences on
prognosis were analysed in univariate analysis
(UA). Then a multivariate analysis (MA) was
performed tor variabies with significance level
p<0.2 in UA. CT seans taken prior to initial
surgery and at the time ot recurrence have been
compared to define the recurrence pattern in
relation to the initial tumour site. Initial and
recurrent tumour were drawn in the simulator
films in order to precise the tailure pattern in
relation to irradiated volume. Survival after
recurrence (SAR) was analysed using Kaplan-
Meier method and prognostic tactors were
analysed using logrank test.
Results: The minimum tollow-up period tor
alive patient was 52 months. The 5- and 10-year
actuarial overall survival rate were 55- and 41 %
respectively. The actuarial progression tree
survival rate were 48% and 29% tor 5 and 10
years respectively. MA revealed that good WHO
performance status (p=0.00001), duration ot
symptoms betore treatment >12 months
(p=0.00003), seizures at presentation
(p=0.0001), age < 45 years (p=0.01) and gross
total resection (p=O.03) are associated with
increased survival.
Median time to recurrence was 49.5 months
(range: 1-134). The precise localisation ot
recurrence was possible in 69 pts (73%). Ali but
three pts recurred within the initial tumour
margin. Two ot them recurred at 1-3 cm ot the
initial tumour margin, one recurred at distance,
in the controlateral hemisphere. The last one
was the only case ot recurrence outside the
previously irradiated volume. Median SAR was 8
Palliative irradiation is given to about 40% ot
cancer patients receiving radiotherapy. The
large number ot patients stand in sharp contrast
to the scarce number ot publications related to
this type ot cancer therapy. It is necessary to
emphasize that palliative radiotherapy should be
administered according to the different principles
than curative treatment. The general principles
governing palliative use ot irradiation, detined by
R. Paterson in 1956, seem to be still valid,
However, since that time a substantial progress
has been made. The main elements ot this
progress, and the main directions of research
are related to:
1. optimisation ot tractionation schedules
/including hyperfractionation/;
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months (range: 0.5-43). Intormation about
treatment ot recurrence was available in 76 pts
(81 %) - (11 - surgery, 9 - surgery and
chemotherapy, 2 - surgery and radiotherapy, 8
- surgery, radiotherapy and chemotherapy, 1 -
radiotherapy, 19 - chemotherapy, 26 -
supportive care). There was no correlation
between any treatment method and patient
related parameters in the Spearman's rank test.
In univariate analysis only addition ot
chemotherapy to recurrence management
(p=O.001) and duration ot symptoms betore
initial surgery >12 months (p=O.004) were
associated with increased SAR. Surgery at
recurrence and patient related parameters (age,
performance status, neurologie function,
seizures) did not intluence survival.
Conclusions: Long-term results ot the
treatment were unfavorable tor a majority of
patients with LGG. Good WHO performance
status, duration ot symptoms betore treatment
>12 months, seizures at presentation, age < 45
years and gross total resection are associated
with increased survival. Our data contirm that
Iimited-volume irradiation tor LGG is an
adequate approach. Management ot tailures
after PRT ot brain tumours remains a
therapeutic challenge. Our results show that
chemotherapy at recurrence signiticantly
improves survival. Surgery was not effective
treatment at recurrence.
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2. re-irradiation;
3. brachytherapy;
4. integration of radiotherapy with the other
methods ot palliative and symptomatic care.
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In addition to c1assical HDR, PDR or LDR
brachytherapy, new techniques such as
transperineal radioactive implantations of the
prostate via template guidance, or vascular
brachytherapy for the prevention of restenosis,
are becoming increasingly popular. At the same
time they are introduced in a department, a
quality assurance program must be
implemented both to minimize the risks of
treatment misadministrations and to prove
respect to legal Iiability.
The authors try to point out the necessary
equipments and the particularities ot Q.A.
programs which must cover all the steps of the
treatment. They consider successively prostate
and vascular brachytherapy, making for each ot
them, a quick review of the most current
techniques (including associated accessories
and imaging devices), showing the particularities
ot adapted computerized treatment planning
systems and the characteristics ot radioactive
sources usually used (photon sources tor
prostate such as 192 Ir tor temporary implants
and 1251 and 103 Pd tor permanent implants, 192 Ir
or beta sources for vessels). Particular detectors
and methods to be employed to pertorm quality
controls of equipments and sources, or in vivo
measurements, are also presented. Lastly the
guidelines and recommendations tor "good
practice and quality assurance" concerning
these particular techniques and published by
different international organizations, or which
are in the process of development, are
summarized. It will be noted that volume
detinitions, dose prescription and reporting,
dose planning, dosimetry, staffing and
responsabilities,etc, are or should be included in
a complete quality assurance program.
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State of the Art: The EQUAL Dosimetry audit
service, set-up by the ESTRO in 1998a, is well-
known through large numbers ot TL-dosimeters
sent to hospitals to be irradiated in clinically
relevant conditions, and read at the EQUAL
Measuring Laboratory, IGR, Villejuit.
Ali European countries have now applied to
participate (404 centres out of 880) for photon
and electron beams. In relation with the IAEA,
this service has been extended to 27 centres ot
7 countries trom Eastern and Central Europe,
and the Mediterranean Basin. 757 photon
beams and 277 electron beams have been
checked according to the "on the beam axis"
procedure.
Results and outcome:
Reference beam output results
demonstrating improvements with respect to
the former EC Network, and good reliability
of the procedure: mean ratios of measured
to stated dose of 0.997 (SD 1.8%) tor
photon beams, and 1.003 (SD 2.1 %) for
electron beams.
Useful service detecting 7% of the photon
beams presenting at least one check point
with a deviation > 5% (2% tor electron
beams, but 3 times more deviations
between 3 and 5%).
Re-checks and on-site visits in 8 centres
reveal inaccuracies in TPS algorithms or
input data and/or in local measurements
(wedge tactors, collimator aperture tactors,
PDD's, beams calibrations).
Conclusion: A number ot dosimetric
problems are still observed, even on the beam
axis. Improvements should be introduced and
checked before considering more sophisticated
treatment techniques.
a The present ESTRO-EQUAL Project (MORQA)
has been tunded by an EU contract.
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